Russell Cohen, MD, is a renowned gastroenterologist with clinical expertise in inflammatory bowel disease (IBD). Under his leadership, a multidisciplinary team of specialists in gastroenterology, surgery, pathology and radiology provide comprehensive care for patients with Crohn's disease and ulcerative colitis.
In addition to his clinical practice, Dr. Cohen is an active researcher. He has served as the principal investigator on several long-term studies designed to test the efficacy and safety of both oral and intravenous drugs in patients with inflammatory bowel disease.
Dr. Cohen serves as associate editor and ad-hoc reviewer for numerous medical journals, including The New England Journal of Medicine and The American Journal of Gastroenterology. He has published more than 30 scientific articles, 50 abstracts and 10 book chapters. He also is the editor of Inflammatory Bowel Disease: Diagnosis and Therapeutics, which is now in its second edition as a leading textbook in this field.
A dedicated educator and mentor, Dr. Cohen teaches medical students, residents and fellows about endoscopes and the pharmacology of gastroenterological drugs. In addition, he is frequently invited to deliver lectures at grand rounds and at national and international conferences on the diagnosis and management of IBD.
Dr. Cohen has been named one of the "Best Doctors in America" by Best Doctors, Inc. for more than 10 consecutive years and is consistently named one of Chicago's "Top Doctors" by Castle Connolly Medical Ltd.
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Jun; 42(6):2970-2971.
PMID: 40293633
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center.
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. Dig Dis Sci. 2025 May; 70(5):1864-1872.
PMID: 40048134
Accelerating Earlier Access to Anti-TNF-a Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease.
Accelerating Earlier Access to Anti-TNF-a Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease. J Clin Med. 2025 Feb 26; 14(5).
PMID: 40095484
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
PMID: 39907897
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry.
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry. Inflamm Bowel Dis. 2025 Jan 08.
PMID: 39779464
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
PMID: 38916136
Editorial.
Editorial. Curr Opin Gastroenterol. 2025 Jan 01; 41(1):1-2.
PMID: 39633584
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease.
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's Disease. Clin Gastroenterol Hepatol. 2024 Oct 24.
PMID: 39461462
A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease.
A Comparative Analysis of Clinical Symptoms and Modified Pouchitis Disease Activity Index Among Endoscopic Phenotypes of the J Pouch in Patients With Inflammatory Bowel Disease. Crohns Colitis 360. 2024 Jul; 6(3):otae045.
PMID: 39347443
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.
Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Jun 25.
PMID: 38916136